Time to Initiated Antitumor Therapy for Tumor Patients With COVID19 Infection

The Seventh Affiliated Hospital of Sun Yat-sen University

Status: Enrolling

Conditions: COVID-19; Tumor

Study type: Observational

Funder types: Other

Identifiers

NCT06006845

pan-01

Details and patient eligibility

About

The goal of this observational study is to study the safety of initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19. The main questions aims to answer are:

• Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases adverse events related to antitumor therapy.
• Whether initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 increases risk of re-infection of COVID-19.
• How initiation of antitumor therapy early after nucleic acid test turn negativity in tumor patients infected with COVID-19 affects QoL of tumor patients

Participants will be asked to answer the question about:

• the severity and duration of COVID-19 symptoms
• the date of diagnosis of COVID-19
• the date of negative nucleic acid test
• the QoL of life before infection with COVID-19, during infection of COVID-19, after nucleic acid test negativity and receiving antitumor therapy

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Tumor patients diagnosed with COVID-19 infection at our center from December 1, 2022 to May 31.
• COVID-19 was confirmed by antigen testing or nucleic acid testing.
• Tumor was confirmed by pathology.
• Patients received systemic antitumor therapy after infected with COVID-19.

Exclusion criteria

• COVID-19 was not confirmed by antigen testing or nucleic acid testing
• Tumor was not confirmed by pathology
• Patients did not receive systemic antitumor therapy
• Patients died before receiving systemic antitumor therapy

Trial design

100 participants in 1 patient group

A

Description:

Tumor patients infected with COVID-19